Vimta Labs Fair Value
Vimta Labs fair value. Vimta Labs (VIMTALABS) average fair value is ₹588.24 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹471.95 (+24.64%), fair value range ₹71.95–₹2252.0.
Fair Value Analysis Export
VIMTALABS Fair Value vs Current Price — Valuation Summary
VIMTALABS average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit Vimta Labs share price today.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Earnings Growth Model (PEG)
Peter Lynch Fair Value
Benjamin Graham Number
Discounted Cash Flow (DCF)
VIMTALABS Fair Value Analysis — Data Sources & Coverage
Vimta Labs financial data sources, valuation methods applied and sector benchmarks used — 2024 financial year. Analyse Vimta Labs ownership pattern to track promoter, FII and institutional holdings.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is 2 years old (2024).
VIMTALABS vs Healthcare Sector Peers — P/E, P/B & Market Cap
Vimta Labs P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 40.6 | 8.3 | ₹44,381 |
| Modern Diagnostic & Rese… | MDRC | - | 1.42 | ₹83 |
| Pharmaids Pharmaceuticals | PHARMAID | -28.7 | 2.2 | ₹100 |
| Glen Industries | GLEN | 15.7 | 1.97 | ₹250 |
| Broach Lifecare Hospital | BROACH | 90.7 | 0.82 | ₹8 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.